Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CAMP4 Therapeutics Corporation (CAMP : NSDQ)

• Company Description    CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases. CAMP4 Therapeutics Corporation is based in CAMBRIDGE, Mass. Number of Employees: 48

• Price / Volume Information    Yesterday's Closing Price: $4.51 Daily Weekly Monthly 20 Day Moving Average: 77,826 shares Shares Outstanding: 51.93 (millions) Market Capitalization: $234.19 (millions) Beta: 0.04 52 Week High: $7.75 52 Week Low: $1.31 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.58% -3.39% 12 Week 0.45% -7.14% Year To Date -26.43% -34.01%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE KENDALL SQUARE BUILDING 1400 WEST 3RD FLOOR - CAMBRIDGE,MA 02139 USA ph: 617-651-8867 fax: - svonderweid@lifesciadvisors.com http://www.camp4tx.com

• General Corporate Information    Officers Josh Mandel-Brehm - President; Chief Executive Officer and Director Douglas Williams - Chairman of the Board Kelly Gold - Chief Financial Officer Michael Higgins - Director Steven Holtzman - Director Peer Information CAMP4 Therapeutics Corporation (CORR.) CAMP4 Therapeutics Corporation (RSPI) CAMP4 Therapeutics Corporation (CGXP) CAMP4 Therapeutics Corporation (BGEN) CAMP4 Therapeutics Corporation (GTBP) CAMP4 Therapeutics Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 13463J101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 51.93 Most Recent Split Date: (:1) Beta: 0.04 Market Capitalization: $234.19 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.23 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.80 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.58 Price/Cash Flow: - Price / Sales: 59.53 EPS Growth vs. Year Ago Period: 48.39% vs. Previous Quarter: 63.22% Sales Growth vs. Year Ago Period: 50.82% vs. Previous Quarter: 271.84% ROE 03/31/26 - -194.74 12/31/25 - -162.49 09/30/25 - -100.10 ROA 03/31/26 - -95.64 12/31/25 - -101.06 09/30/25 - -76.62 Current Ratio 03/31/26 - 6.15 12/31/25 - 7.35 09/30/25 - 9.83 Quick Ratio 03/31/26 - 6.15 12/31/25 - 7.35 09/30/25 - 9.83 Operating Margin 03/31/26 - -2,193.72 12/31/25 - -2,298.54 09/30/25 - -1,404.47 Net Margin 03/31/26 - -2,193.72 12/31/25 - -2,298.54 09/30/25 - -1,404.47 Pre-Tax Margin 03/31/26 - -2,193.72 12/31/25 - -2,298.54 09/30/25 - -1,404.47 Book Value 03/31/26 - 0.60 12/31/25 - 1.02 09/30/25 - 1.25 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.08

Powered by Zacks Investment Research ©